Market Overview

CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Enrolled In A Phase 1/2 Clinical Study Of Ctx001 In Severe Scd In The U.S. And Is Expected To Be Infused With Ctx001 In Mid-2019

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: News

 

Related Articles (VRTX + CRSP)

Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired

28 Stocks Moving In Monday's Pre-Market Session